UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of March 2020
Commission
File Number 001-15170
GlaxoSmithKline plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
GlaxoSmithKline plc
(the 'Company')
Publication of Notice of Annual General Meeting 2020
The Company will shortly publish on its website
(www.gsk.com/en-gb/investors/shareholder-information/annual-general-meeting/) the
Notice of Annual General Meeting 2020 (the '2020 AGM Notice') which
will be distributed to shareholders shortly.
The Company's Annual General Meeting ('AGM') is to be held
on Wednesday 6 May 2020 at 2.30pm at the Sofitel London
Heathrow, Terminal 5, London Heathrow Airport, TW6
2GD.
The evolving COVID-19 situation and the related Government
guidelines will clearly impact the ability of shareholders to
attend our AGM. In normal circumstances, the Board values greatly
the opportunity to meet shareholders in person. However, it
supports fully the recent Government advice for people to avoid
both mass gatherings and all non-essential travel and social
contact and notes that some or all of the recommendations
contained in the Government's guidelines could become mandatory at
any time. On this basis, the Board has
concluded that it is appropriate to strongly urge shareholders not
to attend the AGM in person this year as to do so would be
inconsistent with current Government guidelines relative to
COVID-19 and, instead, to submit proxy votes. These Government guidelines can be found
at www.gov.uk/coronavirus.
Our AGM format this year will be purely functional in format to
comply with the relevant legal requirements. There will be no
presentations or exhibitions. No refreshments or product gift bags
will be provided and any Board members attending the meeting will
not meet with shareholders individually.
Our mission is to do more to help people feel better and live
longer and to that end we seek your assistance to protect our
shareholders, employees and the Board and as a result to enable the
Company to continue to focus on providing healthcare to patients in
need.
Instead of attending this year's AGM, shareholders are asked to
exercise their votes by submitting their proxy electronically or by
post, as explained below. In addition, should a shareholder
have a question that they would have raised at the meeting, we ask
that instead of attending the meeting they send it by email
to [email protected].
Answers to questions will be published on our website following the
AGM.
The situation in relation to COVID-19 continues to develop and the
Company will update shareholders on arrangements for the AGM
through its website at www.gsk.com/en-gb/investors/shareholder-information/annual-general-meeting/.
Shareholders are advised to check the Company's website for updates
or to contact the Company's registrar, Equiniti. Equiniti's contact
details can be found on page 18 of the 2020 AGM
Notice.
Voting
Shareholders are asked to vote on the AGM resolutions by lodging a
proxy so that it is not necessary to be physically present. They
are encouraged to appoint the "Chairman of the meeting" to vote on
their behalf. This can be done by completing a Proxy Form or
submitting proxy instructions electronically. Proxy instructions
must be received by Equiniti by 2.30pm on Monday 4 May
2020.
Participants in the GSK Corporate Sponsored Nominee Service can
exercise their voting rights through Equiniti by completing a Form
of Direction or submitting voting instructions electronically.
Instructions must be received by Equiniti
by 5.00pm on Wednesday 29 April
2020.
Any holder of the Company's shares through a nominee service should
contact their nominee service provider regarding the process for
appointing a proxy to vote on their behalf. The deadline for this
is likely to be before Monday 4 May 2020.
Further details on the appointment of proxies can be found on pages
17 to 19 of the 2020 AGM Notice.
The Board would like to take this opportunity to thank all
shareholders for their continued support and understanding in these
exceptional circumstances and wish them well during this time as we
all navigate the implications of COVID-19. We will return to full
shareholder engagement as soon as feasible.
Please see our website for details on how the Company is
contributing specifically with regard to COVID-19.
In compliance with Listing Rule 9.6.1R of the UK Financial Conduct
Authority, the 2020 AGM Notice will be submitted to the
UK Listing Authority and will, in due course, be available for
inspection at www.morningstar.co.uk/uk/NSM.
V A Whyte
Company Secretary
23 March 2020
GSK - one
of the world's leading research-based pharmaceutical and healthcare
companies - is committed to improving the quality of human life by
enabling people to do more, feel better and live longer. For
further information please visit http://www.gsk.com.
GSK enquiries:
|
|
|
|
Global
Media enquiries:
|
Simon
Steel
|
+44 (0)
20 8047 5502
|
(London)
|
|
Tim
Foley
|
+44 (0) 20 8047 5502
|
(London)
|
|
|
|
|
US
Media enquiries:
|
Sarah
Spencer
|
+1 215
751 3335
|
(Philadelphia)
|
|
|
|
|
Analyst/Investor
enquiries:
|
Sarah Elton-Farr
|
+44 (0) 20 8047 5194
|
(London)
|
|
Danielle Smith
|
+44 (0) 20 8047 0932
|
(London)
|
|
James
Dodwell
|
+44 (0)
20 8047 2406
|
(London)
|
|
Jeff
McLaughlin
|
+1 215
751 7002
|
(Philadelphia)
|
|
|
|
|
Cautionary statement regarding forward-looking
statements
GSK cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such
factors include, but are not limited to, those described under Item
3.D 'Principal risks and uncertainties' in the Company's Annual
Report on Form 20-F for 2019. GSK also refers investors to the
cautionary statement on the inside back cover of the Annual Report
2019.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
GlaxoSmithKline plc
|
|
(Registrant)
|
|
|
Date: March
24, 2020
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GlaxoSmithKline plc
|